Cedars-sinai Medical Center

Prometheus Biosciences, Inc.

Janine Bilsborough

Stephan R Targan

Jeffry Dean Watkins

Cindy T Dickerson

Bradley Henkle

Patricia McNeeley

Dalin Li

Dermot McGovern

Laurens Kruidenier

Mahyar Sabripour

Matthew Reissman

Rafael Rojas

Dermot P Mcgovern

J Monty Watkins

Rebecca Gonsky

Richard L Deem

Philip Fleshner

Provided are methods, systems, and kits for selecting a patient for treatment with a therapeutic agent based on a presence of a genotype associated with a positive therapeutic response to the therapeutic agent. The therapeutic agent, in some embodiments, is an inhibitor of TL1A activity or expression, such as for example, an anti-TL1A antibody.

Methods of enriching or amplifying nucleic acids in a sample from a patient with inflammatory bowel disease

Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), such as Crohn's Disease (CD) and ulcerative colitis (UC).

Humanized antibodies to TNF-like ligand 1A (TL1A) and uses thereof

Optimized anti-TL1A antibodies

Described herein are methods of diagnosing inflammatory bowel disease, including but not limited to Crohn's Disease (CD), Ulcerative Colitis (UC), and/or Medically Refractive Ulcerative Colitis (MR-UC), using RNA-SET2, TL1A and/or IFN-Y. The methods may comprise treating inflammatory bowel disease by administering a therapeutically effective amount of a therapeutic agent to a subject. Described further herein are processes for patient identification and/or stratification.

Methods of diagnosing inflammatory bowel disease through RNASET2

Methods of treating Crohn's disease or ulcerative colitis by administering inhibitors of tumor necrosis factor-like cytokine 1A (TL1A)

Growing community of inventors

Adelaide, Australia

Janine Bilsborough